Predicting survival in melanoma

Annals of Surgical Oncology

Volumn 9, Issue 2, 2002, Pages 113-114

  McMasters, Kelly M ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; EDITORIAL; MELANOMA; METASTASIS; PROGNOSIS; SENTINEL LYMPH NODE;

ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036207924     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2002.9.2.113     Document Type: Editorial

References (6)

1. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
2. A new American Joint Committee on Cancer staging system for cutaneous melanoma
3. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
4. Serum TA90 immune complex assay can predict outcome after resection of thick (>4 mm) primary melanoma and sentinel lymphadenectomy
5. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma
6. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma